Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909047 | 1.00 | KMT2A (0.49) | KMT2AALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL4906646 | 1.00 | KMT2A (0.49) | KMT2AALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL3895456 | 0.92 | ALDH1A1 (0.45) | KMT2AALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL21246536 | 0.88 | ALDH1A1 (0.55) | KMT2AALDH1A1L3MBTL1SLC1A1CA1 | |
| SCHEMBL392233 | 0.85 | LMNA (0.54) | KMT2AALDH1A1HSD17B10L3MBTL1SLC1A1 | |
| SCHEMBL3034357 | 0.84 | SLC1A1 (0.55) | KMT2AALDH1A1CYP2C9CYP2C19SLC1A1 | |
| SCHEMBL800946 | 0.84 | SLC1A1 (0.55) | KMT2AALDH1A1CYP2C9CYP2C19SLC1A1 | |
| SCHEMBL7494382 | 0.84 | SLC1A1 (0.55) | KMT2AALDH1A1CYP2C9CYP2C19SLC1A1 | |
| SCHEMBL2405829 | 0.84 | TDP1 (0.44) | KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2405831 | 0.84 | TDP1 (0.44) | KMT2AALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008531-B2 | Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis | The Florida State University Research Foundation, Inc. (US) | 2011-08-30 | — | — | US | disclosed |
| CN-102010403-A | Total Synthesis of pladienolide B and pladienolide D | EISAI R&D MAN CO LTD | 2011-04-13 | — | — | CN | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915437-B2 | Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| CN-101282967-B | Total synthesis of pladienolide b and pladienolide D | EISAI R&D MAN CO LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20100324324-A1 | Compounds and Methods of Arylmethylation (Benzylation) As Protection For Alcohol Groups During Chemical Synthesis | DUDLEY GREGORY | 2010-12-23 | — | — | US | disclosed |
| US-20100324323-A1 | Compounds and Methods of Arylmethylation (Benzylation) As Protection For Alcohol Groups During Chemical Synthesis | DUDLEY GREGORY | 2010-12-23 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| US-7754909-B1 | Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis | The Florida State University Research Foundation, Inc. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| CN-101282967-A | Total synthesis of pladienolide b and pladienolide D | EISAI R&D MAN CO LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | KMT2A 3422/4885ALDH1A1 1662/4885THRB 1168/4885 |
| US-20100324323-A1 | Compounds and Methods of Arylmethylation (Benzylation) As Protection For Alcohol Groups During Chemical Synthesis | ADH1C, ADH1A, CYP2E1 | KMT2A 451/4885ALDH1A1 66/4885THRB 1482/4885 |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | CYP8B1, PLA2G2D, HPD | KMT2A 4159/4885ALDH1A1 2637/4885THRB 1685/4885 |
| US-20100324324-A1 | Compounds and Methods of Arylmethylation (Benzylation) As Protection For Alcohol Groups During Chemical Synthesis | ADH1C, ADH1A, CYP2E1 | KMT2A 451/4885ALDH1A1 66/4885THRB 1482/4885 |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | TPD52L2, CYP8B1, HPD | KMT2A 3829/4885ALDH1A1 2011/4885THRB 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.